These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 31430492

  • 1. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
    Xu B, Dogan S, Haroon Al Rasheed MR, Ghossein R, Katabi N.
    Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
    [Abstract] [Full Text] [Related]

  • 2. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
    Yang RK, Zhao P, Lu C, Luo J, Hu R.
    Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779
    [Abstract] [Full Text] [Related]

  • 3. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
    Udager AM, Chiosea SI.
    Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
    [Abstract] [Full Text] [Related]

  • 4. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM, Senarathne W, Feldman R, Florento E, Stafford P, Swensen J, Vranic S, Gatalica Z.
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [Abstract] [Full Text] [Related]

  • 5. The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases.
    Urano M, Hirai H, Tada Y, Kawakita D, Shimura T, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Fushimi C, Shimizu A, Takase S, Okada T, Sato H, Imanishi Y, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Sato Y, Saigusa N, Nakaguro M, Hanazawa T, Nagao T.
    Histopathology; 2018 Dec; 73(6):943-952. PubMed ID: 29993139
    [Abstract] [Full Text] [Related]

  • 6. The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center.
    Mayer M, Wolber P, Prinz J, Jansen L, Esser J, Shabli S, Quaas A, Klußmann JP, Sharma SJ, Nachtsheim L, Arolt C.
    Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3779-3789. PubMed ID: 38587651
    [Abstract] [Full Text] [Related]

  • 7. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.
    Mitani Y, Rao PH, Maity SN, Lee YC, Ferrarotto R, Post JC, Licitra L, Lippman SM, Kies MS, Weber RS, Caulin C, Lin SH, El-Naggar AK.
    Clin Cancer Res; 2014 Dec 15; 20(24):6570-81. PubMed ID: 25316813
    [Abstract] [Full Text] [Related]

  • 8. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
    van Boxtel W, Verhaegh GW, van Engen-van Grunsven IA, van Strijp D, Kroeze LI, Ligtenberg MJ, van Zon HB, Hendriksen Y, Keizer D, van de Stolpe A, Schalken JA, van Herpen CM.
    Int J Cancer; 2020 Jun 01; 146(11):3196-3206. PubMed ID: 31745978
    [Abstract] [Full Text] [Related]

  • 9. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.
    Dalin MG, Desrichard A, Katabi N, Makarov V, Walsh LA, Lee KW, Wang Q, Armenia J, West L, Dogan S, Wang L, Ramaswami D, Ho AL, Ganly I, Solit DB, Berger MF, Schultz ND, Reis-Filho JS, Chan TA, Morris LG.
    Clin Cancer Res; 2016 Sep 15; 22(18):4623-33. PubMed ID: 27103403
    [Abstract] [Full Text] [Related]

  • 10. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma.
    Kapadia SB, Barnes L.
    Mod Pathol; 1998 Nov 15; 11(11):1033-8. PubMed ID: 9831198
    [Abstract] [Full Text] [Related]

  • 11. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
    Jeong JS, Cho KJ, Kim D, Lee YS, Song JS.
    Pathol Res Pract; 2021 Dec 15; 228():153678. PubMed ID: 34781210
    [Abstract] [Full Text] [Related]

  • 12. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
    van Boxtel W, Locati LD, van Engen-van Grunsven ACH, Bergamini C, Jonker MA, Fiets E, Cavalieri S, Tooten S, Bos E, Quattrone P, Verhaegh GW, Schalken JA, Licitra L, van Herpen CML, PALGA Group.
    Eur J Cancer; 2019 Mar 15; 110():62-70. PubMed ID: 30771738
    [Abstract] [Full Text] [Related]

  • 13. Salivary duct carcinoma with squamous differentiation: histomorphological and immunophenotypical analysis of six cases.
    Dababneh MN, Griffith CC, Magliocca KR, Stojanov IJ.
    Histopathology; 2024 Oct 15; 85(4):590-597. PubMed ID: 38828680
    [Abstract] [Full Text] [Related]

  • 14. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
    Santana T, Pavel A, Martinek P, Steiner P, Grossmann P, Baněčková M, Skálová A.
    Hum Pathol; 2019 Nov 15; 93():37-47. PubMed ID: 31437521
    [Abstract] [Full Text] [Related]

  • 15. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance.
    Nagao T, Gaffey TA, Visscher DW, Kay PA, Minato H, Serizawa H, Lewis JE.
    Am J Surg Pathol; 2004 Mar 15; 28(3):319-26. PubMed ID: 15104294
    [Abstract] [Full Text] [Related]

  • 16. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature.
    Fan CY, Wang J, Barnes EL.
    Am J Surg Pathol; 2000 Apr 15; 24(4):579-86. PubMed ID: 10757407
    [Abstract] [Full Text] [Related]

  • 17. A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.
    Weijers JAM, Verhaegh GW, Lassche G, van Engen-van Grunsven ACH, Driessen CML, van Erp NP, Jonker MA, Schalken JA, van Herpen CML.
    BMC Cancer; 2024 Sep 20; 24(1):1174. PubMed ID: 39304797
    [Abstract] [Full Text] [Related]

  • 18. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
    Boon E, Bel M, van Boxtel W, van der Graaf WTA, van Es RJJ, Eerenstein SEJ, Baatenburg de Jong RJ, van den Brekel MWM, van der Velden LA, Witjes MJH, Hoeben A, Willems SM, Bloemena E, Smit LA, Oosting SF, PALGA Group, Jonker MA, Flucke UE, van Herpen CML.
    Int J Cancer; 2018 Aug 15; 143(4):758-766. PubMed ID: 29492965
    [Abstract] [Full Text] [Related]

  • 19. Salivary duct carcinoma cytologically diagnosed distinctly from salivary gland carcinomas with squamous differentiation.
    Kawahara A, Harada H, Akiba J, Kage M.
    Diagn Cytopathol; 2008 Jul 15; 36(7):485-93. PubMed ID: 18528886
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemical expression of mammaglobin in salivary duct carcinomas de novo and salivary duct carcinoma ex pleomorphic adenoma.
    Soares CD, de Lima Morais TM, Carlos R, Martins MD, de Almeida OP, Mariano FV, Altemani A.
    Hum Pathol; 2019 Oct 15; 92():59-66. PubMed ID: 31400353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.